NESS ZIONA, Israel, July 9 /PRNewswire/ -- Foamix Ltd. announced today that the Company has been selected to present at the 34th Annual Meeting of the Controlled Release Society.
A poster entitled “Bio-adhesive Vaginal Foam: In-Vitro and In-Vivo Adhesion Profile” will be presented by Foamix’s CTO, Dr. Doron Friedman, at the 34th Annual Meeting of the Controlled Release Society (CRS) in Long Beach, California, US July 7-11, 2007. The abstract will also be published in CRS Journal.
Foamix accomplished its objective to be the first to develop a new type of vaginal foam vehicle. While topical formulations, such as creams, lotions, gels and ovules, are commonly used for delivery to the vaginal cavity, they are often reported to be messy, require complicated administration and can leak out after treatment, causing discomfort to the patients. Foamix’s unique vaginal foam is an easy-to-use vaginal delivery system, which is simple to operate and requires minimal preparation. Vaginal foam is composed of delicate FDA approved ingredients and it is well tolerated. The foam expands gently and spreads evenly over the entire vaginal cavity surface; and it also effectively reaches the cervix. The Foamix vaginal foams are bio-adhesive, do not leak following application and thus, they can retain an active agent intra-vaginally for prolonged periods of time.
“We are excited to unveil our innovative intravaginal foam technology, and we are pleased that CRS has given us the opportunity to do so. Foam offers properties that increase usability, encourage compliance and boost user satisfaction. Our foams can effectively deliver a broad range of drugs; they are non-drip, with easy application, thus making them uniquely suitable for gynecologic application,” said Foamix CEO Dr. Dov Tamarkin.
The poster (Poster Number 377 in Poster Session I) will be presented in Hall A at the Long Beach Convention Center and will be available for viewing by meeting attendees on Monday, July 9 from 10:00 am to 10:45 am and from 15:00 pm to 16:00 pm. To read the poster, please visit: http://www.foamix.co.il/CRS poster.pdf
Note: Foamix will be exhibiting at the American Academy of Dermatology (AAD), August 1-5, 2007 at the Hilton New York, NY. Interested parties are invited to stop by our booth for a briefing and demonstration. To schedule an appointment at AAD 2007, please contact our US representative Mr. Charlie Harrison at charlie@foamix.co.il; phone: +1-404-229-1499.
About Foamix
Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, stable foam products for prescription, OTC and cosmetic applications. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. We currently collaborate with 8 pharmaceutical companies on 10 projects in the development of proprietary dermatological and gynaecologic foam drugs; and we have our own in-house pipeline of dermatological and gynecological drugs in foam presentation.
The company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix holds 3 patens and has 42 patents pending.
For additional information please visit www.foamix.co.il Press inquiries: Sigal Maymon Foamix Ltd +972-8-9316233 info@foamix.co.il
Foamix Ltd
CONTACT: Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 orinfo@foamix.co.il
